红花对局灶节段性肾小球硬化大鼠血纤溶酶原激活物及纤溶酶原激活.docVIP

红花对局灶节段性肾小球硬化大鼠血纤溶酶原激活物及纤溶酶原激活 　【摘要】 　　目的探讨红花对局灶节段性肾小球硬化（FSGS）大鼠纤溶酶原激活物（t-PA）及纤溶酶原激活物抑制物-1(PAI-1)的干预作用。方法40只SD大鼠随机分为假手术组、模型组、缬沙坦组和红花组，每组10只，除假手术组外，其余3组用一侧肾切除加尾静脉注射阿霉素的方法复制FSGS大鼠模型，同时，第1次尾静脉注射1周后红花组灌服红花4g/kg·d；缬沙坦组灌服缬沙坦10 mg/kg·d。8周末采用酶联免疫吸附法（ELISA）测定血t-PA、PAI-1的含量，并进行光镜检查。结果各组之间t-PA的含量无明显差异（P＞0.05）。模型组PAI-1含量与假手术组相比明显升高（Plt;0.01）；缬沙坦组、红花组与模型组比较PAI-1含量明显降低（Plt;0.01），缬沙坦组与红花组之间无明显差异（P＞0.05）。结论FSGS模型大鼠存在着PAI-1的高表达，红花能减少血PAI-1的表达，纠正纤溶系统的紊乱，延缓其病理进程。 【关键词】 红花 局灶节段性肾小球硬化 纤溶系统 　　Abstract：ObjectiveTo survey the effect of Honghua on blood t-PA and PAI-1 in Focal Segmental Golmerulosclerosis(FSGS) rats.Methods40 SD male rats were divided into four groups:sham operation group,model group,Valsartan group and HongHua group.Each animal adopted one side nephrectomy and tail intravenous injection of A driamycin except Sham group.Drugs were administered from the seventh day after operation.The expression of t-PA and PAI-1 was detected by ELISA and the pathological change was observed.ResultsThere had no significant differences for the relative content of t-PA between each group(P＞0.05）.The relative content of PAI-1 in model group was significantly higher than that of sham group(P＜0.01),and the contents in Valsartan group and Honghua group were significantly lower than that in model group(P＜0.01),but there was no significant difference between Valsartan group and Honghua group.ConclusionThe expression of PAI-1 is high in FSGS rats.Honghua can retrieve the expression of PAI-1 and adjust the unbalance of t-PA and PAI-1,reduce the lesion of pathology. 　　Key words：Honghua; FSGS; Activator of plasminogen; Plasminogen activator inhibitor 　　局灶节段性肾小球硬化（FSGS）为难治性肾病的主要病理类型，一般在临床症状发作后10年左右进入终末期肾功能衰竭，导致肾小球硬化及间质纤维化。纤溶系统功能障碍与肾小球硬化及间质纤维化的形成密切相关。本实验利用一侧肾切除加尾静脉注射阿霉素的方法复制FSGS大鼠模型，同时以缬沙坦作对照，观察红花对FSGS大鼠纤溶酶原激活物（t-PA）及纤溶酶原激活物抑制物-1（PAI-1）的干预作用，为红花在临床中的应用提供实验依据。 　　1 器材 　　1.1 动物 健康雄性SD大鼠40只，体重为（180±10）g，由河北医科大学动物中心提供。 　　1.2 药品与试剂 红花，为免煎中药饮片，6 g/袋，由三九医药股份有限公司提供；阿霉素粉剂，10 mg/瓶，系上海华联制药有限公司产品。 　　2 方法 　　2.1 动物与分